Inhibition of Xanthine Oxidoreductase Enhances the Potential of Tyrosine Kinase Inhibitors against Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is characterized by the expression of the oncogenic kinase BCR-ABL. Although tyrosine kinase inhibitors (TKIs) against BCR-ABL represent the standard therapeutic option for CML, resistances to TKIs can be a serious problem. Thus, the search for novel therapeutic approa...

Descripción completa

Detalles Bibliográficos
Autores principales: Romo-González, Marta, Moreno-Paz, Sara, García-Hernández, Violeta, Sánchez-Guijo, Fermín, Hernández-Hernández, Ángel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7022995/
https://www.ncbi.nlm.nih.gov/pubmed/31952182
http://dx.doi.org/10.3390/antiox9010074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7022995/
https://www.ncbi.nlm.nih.gov/pubmed/31952182
http://dx.doi.org/10.3390/antiox9010074

Ejemplares similares